Optimal timing and treatment strategy for pancreatic cancer.

ABSTRACT:

Background

For pancreatic adenocarcinoma (PDAC), no studies have established any association between earlier treatment initiation and long-term outcomes. In addition, an optimal type of initial treatment for the localized disease remains ill-defined.

Methods

Patients in the National Cancer Database (2004-2015) with clinical stage I (CS-I) and II (CS-II) PDAC who underwent curative-intent resection were included. Optimal time from diagnosis-to-treatment including neoadjuvant chemotherapy, neoadjuvant chemoradiation, or upfront surgery was assessed. An optimal type of treatment was evaluated. The primary outcome was overall survival (OS).

Results

Among 29 167 patients, starting any treatment within 0 to 6 weeks was associated with improved median OS compared with 7 to 1

SUBMITTER: Gamboa AC 

PROVIDER: S-EPMC7396281 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature